Search hospitals > South Dakota > Rapid City
Rapid City Regional Hospital
Claim this profileRapid City, South Dakota 57701
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Brain Tumor
Conducts research for Pancreatic Cancer
Conducts research for Cancer
397 reported clinical trials
11 medical researchers
Summary
Rapid City Regional Hospital is a medical facility located in Rapid City, South Dakota. This center is recognized for care of Breast Cancer, Lung Cancer, Brain Tumor, Pancreatic Cancer, Cancer and other specialties. Rapid City Regional Hospital is involved with conducting 397 clinical trials across 426 conditions. There are 11 research doctors associated with this hospital, such as Abdel-Ghani Azzouqa, Helen L. Frederickson, Bhaskar Purushottam, and Alexander Schabauer.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
Stage IV
2Lung Cancer
Global LeaderStage IV
Stage III
Stage I
Top PIs
Abdel-Ghani AzzouqaRapid City Regional Hospital2 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
22 reported clinical trials
65 drugs studied
Helen L. FredericksonRapid City Regional Hospital7 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
3 reported clinical trials
4 drugs studied
Bhaskar PurushottamMonument Health4 years of reported clinical research
Studies Cardiovascular Disease
Studies Coronary Artery Disease
3 reported clinical trials
4 drugs studied
Alexander SchabauerMonument Health Rapid City Hospital4 years of reported clinical research
Studies Obesity
Studies Heart Failure
2 reported clinical trials
4 drugs studied
Clinical Trials running at Rapid City Regional Hospital
Breast Cancer
Lung Cancer
Esophageal cancer
Cancer
Heart Failure
Ovarian Cancer
Liver Cancer
Breast cancer
Melanoma
Throat Cancer
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting2 awards Phase 38 criteria
HER2-Targeted Therapy
for Breast Cancer
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called HER2. HER2 is found on some cancer cells. When trastuzumab or pertuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving 6 months of HER2-targeted therapy may work better than giving 12 months for the treatment of HER2+ breast cancer in patients that had a pCR after neoadjuvant chemotherapy with trastuzumab.
Recruiting2 awards Phase 35 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Rapid City Regional Hospital?
Rapid City Regional Hospital is a medical facility located in Rapid City, South Dakota. This center is recognized for care of Breast Cancer, Lung Cancer, Brain Tumor, Pancreatic Cancer, Cancer and other specialties. Rapid City Regional Hospital is involved with conducting 397 clinical trials across 426 conditions. There are 11 research doctors associated with this hospital, such as Abdel-Ghani Azzouqa, Helen L. Frederickson, Bhaskar Purushottam, and Alexander Schabauer.
Where is Rapid City Regional Hospital located?
**Rapid City Regional Hospital**
Location: 353 Fairmont Boulevard, Rapid City, South Dakota. Access is available from Fifth Street or Third Street via Fairmont Boulevard.
Who should I call to ask about financial aid or insurance network?
For billing and insurance-related questions at Rapid City Regional Hospital, part of Monument Health, contact the Patient Financial Services department at 605-755-2455. They offer assistance with understanding care costs, insurance coverage, payment options, and setting up payment plans for those unable to pay the full bill amount. Monument Health also provides Financial Assistance Programs for qualifying patients, which may significantly reduce or eliminate the cost of services. Applications for financial assistance are available in multiple languages and can be submitted through MyChart, by phone, or in person at any Monument Health Hospital or Clinic's Admission/Registration or Emergency Department.
What insurance does Rapid City Regional Hospital accept?
Rapid City Regional Hospital, part of Monument Health, accepts all major insurances. Patients are advised to verify with their insurance provider that Monument Health is in-network. Monument Health participates in Medicaid programs for South Dakota, Minnesota, Montana, Nebraska, and Wyoming, and offers a Financial Assistance Program for eligible care.
What awards or recognition has Rapid City Regional Hospital received?
Rapid City Regional Hospital, part of Monument Health, boasts a 5-star rating from the Centers for Medicare & Medicaid Services (CMS) and has earned numerous accolades including the Joint Commission's Gold Seal of Approval and ENERGY STAR certification. It has been recognized as a top 100 rural hospital in America and has received awards such as the ACTION Registry Platinum Performance Achievement Award and the Get With The GuidelinesĀ® Stroke Gold Plus Quality Achievement Award from the American Heart Association. The hospital is also a MBSAQIP Accredited Comprehensive Center, has ISCD Accreditation for its DXA department, and was honored with the Equity of Care, Small/Rural Hospital Excellence Award from the American Hospital Association in 2023.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.